The combination of durvalumab and proton beam therapy (accelerated fractionated RT) in patients with non-PD-L1 selective LA-NSCLC is ongoing [CASE1518 (NCT03818776)]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.